60 디그리스 파마슈티컬스SXTP 주가

Ascendiant Capital Maintains Buy on 60 Degrees, Lowers Price Target to $3.7

Ascendiant Capital analyst Lucas Ward maintains 60 Degrees (NASDAQ:SXTP) with a Buy and lowers the price target from $4.2 to $3.7.

HC Wainwright & Co. Downgrades 60 Degrees to Neutral

HC Wainwright & Co. analyst Matthew Keller downgrades 60 Degrees (NASDAQ:SXTP) from Buy to Neutral.

[3] 3

[8-K] 중대 사건 — CURRENT REPORT

60 Degrees Q1 EPS $(1.28) Misses $(0.76) Estimate, Sales $76.377K Miss $435.000K Estimate

60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(0.76) by 68.42 percent. This is a 79.52 percent increase over losses of $(6.25) per share from the

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

WASHINGTON, May 15, 2026 -- 60 Degrees Pharmaceuticals, Inc.  , a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the...

♻️ 재탕[SCHEDULE 13G/A] SCHEDULE 13G/A

♻️ 재탕[SCHEDULE 13G/A] SCHEDULE 13G/A

[10-Q] 분기 실적 — 10-Q

[SCHEDULE 13G/A] SCHEDULE 13G/A